Beijing Minhai Biotechnology Co Ltd – Product Pipeline Review

Global Markets Direct’s, ‘Beijing Minhai Biotechnology Co Ltd – Product Pipeline Review – 2016’, provides an overview of the Beijing Minhai Biotechnology Co Ltd’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Beijing Minhai Biotechnology Co Ltd, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the pipeline therapeutic landscape of Beijing Minhai Biotechnology Co Ltd

The report provides overview of Beijing Minhai Biotechnology Co Ltd including its business description, key facts, and locations and subsidiaries

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report assesses Beijing Minhai Biotechnology Co Ltd’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report features Beijing Minhai Biotechnology Co Ltd’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

Evaluate Beijing Minhai Biotechnology Co Ltd’s strategic position with total access to detailed information on its product pipeline

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Beijing Minhai Biotechnology Co Ltd

Identify potential new clients or partners in the target demographic

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Beijing Minhai Biotechnology Co Ltd’s pipeline depth and focus of pipeline therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Beijing Minhai Biotechnology Co Ltd Snapshot 7

Beijing Minhai Biotechnology Co Ltd Overview 7

Key Facts 7

Beijing Minhai Biotechnology Co Ltd - Research and Development Overview 8

Key Therapeutic Areas 8

Beijing Minhai Biotechnology Co Ltd - Pipeline Review 11

Pipeline Products by Stage of Development 11

Pipeline Products - Monotherapy 12

Pipeline Products - Combination Treatment Modalities 13

Pipeline Products - Partnered Products 14

Partnered Products/Combination Treatment Modalities 15

Beijing Minhai Biotechnology Co Ltd - Pipeline Products Glance 16

Beijing Minhai Biotechnology Co Ltd - Late Stage Pipeline Products 16

Pre-Registration Products/Combination Treatment Modalities 16

Phase III Products/Combination Treatment Modalities 17

Beijing Minhai Biotechnology Co Ltd - Clinical Stage Pipeline Products 18

Phase I Products/Combination Treatment Modalities 18

Beijing Minhai Biotechnology Co Ltd - Early Stage Pipeline Products 19

IND/CTA Filed Products/Combination Treatment Modalities 19

Preclinical Products/Combination Treatment Modalities 20

Beijing Minhai Biotechnology Co Ltd - Drug Profiles 21

(diphtheria + Haemophilus influenza [serotype B] + pertussis (acellular) + polio + tetanus) vaccine - Drug Profile 21

Product Description 21

Mechanism Of Action 21

R&D Progress 21

(diphtheria + pertussis (acellular) + tetanus) vaccine - Drug Profile 22

Product Description 22

Mechanism Of Action 22

R&D Progress 22

(hepatitis A + hepatitis B) vaccine - Drug Profile 23

Product Description 23

Mechanism Of Action 23

R&D Progress 23

(measles + rubella + varicella) vaccine - Drug Profile 24

Product Description 24

Mechanism Of Action 24

R&D Progress 24

cholera (trivalent) vaccine - Drug Profile 25

Product Description 25

Mechanism Of Action 25

R&D Progress 25

Enterovirus [serotype EV-A71] vaccine - Drug Profile 26

Product Description 26

Mechanism Of Action 26

R&D Progress 26

Haemophilus influenzae B vaccine - Drug Profile 27

Product Description 27

Mechanism Of Action 27

R&D Progress 27

hepatitis A vaccine - Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

hepatitis B vaccine - Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

herpes simplex virus vaccine - Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

herpes zoster vaccine - Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

human papillomavirus (quadrivalent) vaccine - Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

influenza (split virion) vaccine - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

influenza [strain A/H1N1] vaccine - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

influenza [strain A/H7N9] vaccine - Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

meningococcal [serotype B] vaccine - Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

meningococcal [serotypes A, C, W-135, Y] (tetravalent) vaccine - Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

meningococcal [serotypes A, C, W-135, Y] (tetravalent) vaccine 2 - Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

mumps vaccine - Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

pneumococcal (13-valent) vaccine - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

pneumococcal (23-valent) vaccine - Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

rabies vaccine - Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

rotavirus (pentavalent) vaccine - Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

varicella zoster vaccine - Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

Beijing Minhai Biotechnology Co Ltd - Pipeline Analysis 45

Beijing Minhai Biotechnology Co Ltd - Pipeline Products by Route of Administration 45

Beijing Minhai Biotechnology Co Ltd - Pipeline Products by Molecule Type 46

Beijing Minhai Biotechnology Co Ltd - Dormant Projects 47

Beijing Minhai Biotechnology Co Ltd - Locations And Subsidiaries 48

Head Office 48

Appendix 49

Methodology 49

Coverage 49

Secondary Research 49

Primary Research 49

Expert Panel Validation 49

Contact Us 49

Disclaimer 50

List of Tables

List of Tables

Beijing Minhai Biotechnology Co Ltd, Key Facts 7

Beijing Minhai Biotechnology Co Ltd – Pipeline by Indication, 2016 9

Beijing Minhai Biotechnology Co Ltd – Pipeline by Stage of Development, 2016 11

Beijing Minhai Biotechnology Co Ltd – Monotherapy Products in Pipeline, 2016 12

Beijing Minhai Biotechnology Co Ltd – Combination Treatment Modalities in Pipeline, 2016 13

Beijing Minhai Biotechnology Co Ltd – Partnered Products in Pipeline, 2016 14

Beijing Minhai Biotechnology Co Ltd – Partnered Products/ Combination Treatment Modalities, 2016 15

Beijing Minhai Biotechnology Co Ltd – Pre-Registration, 2016 16

Beijing Minhai Biotechnology Co Ltd – Phase III, 2016 17

Beijing Minhai Biotechnology Co Ltd – Phase I, 2016 18

Beijing Minhai Biotechnology Co Ltd – IND/CTA Filed, 2016 19

Beijing Minhai Biotechnology Co Ltd – Preclinical, 2016 20

Beijing Minhai Biotechnology Co Ltd – Pipeline by Route of Administration, 2016 45

Beijing Minhai Biotechnology Co Ltd – Pipeline by Molecule Type, 2016 46

Beijing Minhai Biotechnology Co Ltd – Dormant Developmental Projects,2016 47

List of Figures

List of Figures

Beijing Minhai Biotechnology Co Ltd – Pipeline by Top 10 Indication, 2016 9

Beijing Minhai Biotechnology Co Ltd – Pipeline by Stage of Development, 2016 11

Beijing Minhai Biotechnology Co Ltd – Monotherapy Products in Pipeline, 2016 12

Beijing Minhai Biotechnology Co Ltd – Combination Treatment Modalities in Pipeline, 2016 13

Beijing Minhai Biotechnology Co Ltd – Pipeline by Route of Administration, 2016 45

Beijing Minhai Biotechnology Co Ltd – Pipeline by Molecule Type, 2016 46

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports